Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Lymphoma and Melanoma

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3282
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Lymphoma and Melanoma in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Leukemia, Lymphoma and Melanoma.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Melanoma.

    To find out more about Triple Analysis: Leukemia, Lymphoma and Melanoma, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Lymphoma and Melanoma is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Leukemia, Lymphoma and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part III: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

This Report Includes the Following Companies:
3M Pharmaceuticals
3SBio
4SC
AB Science
Abbott
AbbVie
Abiogen
Actelion
Actinium Pharmaceuticals
Adherex
Advanced Life Sciences
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Alexion
Alfa Wassermann
Alfacell
Allos Therapeutics
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Amgen
AngioChem
Antisense Pharma
Antisoma
Aphios
ApopLogic Pharmaceuticals
Apotex
Apricus Biosciences
Arca biopharma
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
Bayer
Benitec
Bio-Medisinsk Innovasjon
Bio-Path Holdings
BioAlliance Pharma
Biocon
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biokine Therapeutics
Biolex
BioNTech
BioNumerik
BioSante
Biosceptre
Biotech Ltd
Biotecnol
Bioton
BioVex
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celtic Pharma
Cephalon
Choongwae
CJ Corp
Clavis Pharma
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CSL
Curacyte
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokinetics
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DiaMedica
DNAVEC
Dong-A
Dr Reddy’s
Dynavax Technologies
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
Favrille
Flamel Technologies
Forma Therapeutics
Gemin X Biotechnologies
Genencor
Genentech
Genmab
GenPat77
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GlycoMimetics
Gradalis
Hanmi
Hayashibara
Heber Biotec
HemaQuest
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
IDM Pharma
IGF Oncology
IkerChem
ImClone Systems
Immune Pharmaceuticals
Immunocore
ImmunoGen
Immunomedics
Immunovaccine
ImmuPharma
Incyte Corporation
InDex Pharmaceuticals
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inotek
Inovio
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Intrexon
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Italfarmaco
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
KaloBios
Kalypsys
Kanisa
Karyon-CTT
Kiadis
Kinex
Kissei
Kyowa Hakko Kirin
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Meda
MediGene
MedImmune
Medisyn Technologies
Memgen
Merck & Co
Merck KGaA
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
NIH
Nippon Shinyaku
Non-industrial source
Novartis
Novogen
Noxxon
Nycomed Pharma
Oasmia
Oncalis
Onconova
Oncothyreon
Oncovir
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
Pacific Biotech
Patrys
PBL Therapeutics
Pfizer
Pharmacyclics
PharmaMar
Philogen
PhiloGene
PIERIS Proteolab
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Prochon Biotech
Progen
ProMetic Life Sciences
ProNAi Therapeutics
Reata Pharmaceuticals
Regeneron
Regulon
Reliance Life Sciences
Rexahn
Rigel
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Santhera Pharmaceuticals
Sareum
SBI Biotech
SBIO
Scancell
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Sepal Pharma
Servier
Shenogen
Shire
Sidus
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Southern Research Institute
Spirogen
Stemline Therapeutics
Sunesis
SuperGen
SuppreMol
Swedish Orphan Biovitrum
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
Synta Pharmaceuticals
Syntrix
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Targepeutics
Tau Therapeutics
TeGenero
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Titan Pharmaceuticals
to-BBB
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
Vaccinex
Valeant
VBL Therapeutics
Vectura
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Vical
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
WntResearch
XBiotech
Xencor
Xerion
Yakult Honsha
Yamasa Corporation
York Pharma
Zenotech
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
AEB071
agatolimod
aldesleukin
alemtuzumab
ALT-801
amonafide malate
amrubicin hydrochloride
amsacrine
APO-866
ARRY-438162
astuprotimut-r
Auto TAG vaccine
axitinib
barasertib
bardoxolone methyl
belinostat
bevacizumab
bexarotene
bisantrene
BMS-663513
BMS-936558
bortezomib
bosutinib
brentuximab vedotin
Buparlisib
Cabozantinib
CB-10-01
cilengitide
cladribine
clofarabine
cositecan
CSF-GM
CT-011
cytarabine ocfosfate
cytarabine, injectable
dasatinib
daunorubicin
decitabine
denenicokin
denileukin diftitox
dinaciclib
dovitinib lactate
E7449
elacytarabine
elliptinium acetate
EMD-273063
endostatin
enocitabine
entinostat
enzastaurin hydrochloride
epirubicin
everolimus
Exherin
fresolimumab
galiximab
ganetespib
ganitumab
gefitinib
gemtuzumab ozogamicin
glembatumumab vedotin
golvatinib
GSK-1120212
GSK-2118436
GV-1001
GVAX
HBP-347
Hi-8 MEL
histamine dihydrochloride
ibritumomab tiuxetan
idarubicin
imatinib mesilate
INCB-24360
inotuzumab ozogamicin
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
interleukin-12
interleukin-2
intetumumab
IPH-1101
ipilimumab
irinotecan hydrochloride
ispinesib mesylate
JX-594
kahalalide F
L19-IL2
Lambrolizumab
LEE-011
lenvatinib
lestaurtinib
leukemia vaccine
LGX818
LipoVIL12
lumiliximab
MDX-1379
MetXia
MGN-1601
midostaurin
mitoxantrone
MKC-1106-MT
MORAb-004
nilotinib
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
OncoVAX
P276-00
panobinostat
peginterferon alfa-2b
pentostatin
perifosine
pimasertib
pixantrone
plitidepsin
poly-ICLC
pralatrexate
RAF-265
ramucirumab
razoxane
Reditux
retaspimycin
rhIFN-alpha
ridaforolimus
rintatolimod
rituximab
romidepsin
sagopilone
sargramostim
SCIB-1
selumetinib
sobuzoxane
sunitinib malate
talminogene laherparepvec
tamibarotene
temsirolimus
teniposide
tesetaxel
thalidomide
thymalfasin
tipifarnib
trabedersen
tremelimumab
velimogene aliplasmid
veliparib
vemurafenib
verubulin
vinflunine ditartrate
vitespen
volociximab
vosaroxin
YM-155
zanolimumab
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Melanoma.
    To find out more about Triple Analysis: Leukemia, Lymphoma and Melanoma, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Lymphoma and Melanoma is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Learn More


Triple Analysis: Breast Cancer, Lung Cancer and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lung Cancer and by the mechanism/target/effect of Apoptosis. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Leukemia, Lymphoma and Peptides
This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the compound strategy of Peptides. Learn More


Target Atlas in Oncology Drug Development: Targeted Therapies
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances. Learn More